Strategies to minimize CNS toxicity: In vitro high-throughput assays and computational modeling

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 5, 2012, Pages 531-542

  Wager, Travis T ^a   Liras, Jennifer L ^a   Mente, Scot ^a   Trapa, Patrick ^a  

^a PFIZER INC   (United States)

Author keywords

adenosine triphosphate binding cassette (ABC) transporters; adverse drug reaction; bloodbrain barrier; brain availability; CNS toxicity; high throughput screens; p glycoprotein; physicochemical properties; physiologically based pharmacokinetic modeling

Indexed keywords

AGENTS ACTING ON THE PERIPHERAL NERVOUS AND NEUROMUSCULAR SYSTEMS;

AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; CENTRAL NERVOUS SYSTEM TOXICITY; DRUG DESIGN; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG UPTAKE; GASTROINTESTINAL ABSORPTION; HIGH THROUGHPUT SCREENING; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; NEUROTOXICITY; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; REVIEW;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; COMPUTER SIMULATION; DRUG TOXICITY; HUMANS; PHARMACOKINETICS; PHYSICOCHEMICAL PHENOMENA;

EID: 84860001254     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.677028     Document Type: Review

References (83)

1. Azevedo FAC, Carvalho LRB, Grinberg LT, et al. Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. J Comp Neurol 2009;513(5):532-41
2. Hitchcock SA, Pennington LD. Structure-brain exposure relationships. J Med Chem 2006;49(26):7559-83 (Pubitemid 46033646)
3. Abbott NJ, Patabendige AAK, Dolman DEM, et al. Structure and function of the blood-brain barrier. Neurobiol Dis 2010;37(1):13-25
4. Easter A, Bell ME, Damewood JR Jr, et al. Approaches to seizure risk assessment in preclinical drug discovery. Drug Discovery Today 2009;14(17-18):876-84
5. Nishioku T, Yamauchi A, Takata F, et al. Disruption of the blood-brain barrier in collagen-induced arthritic mice. Neurosci Lett 2010;482(3):208-11
6. del Zoppo GJ, Hallenbeck JM. Advances in the vascular pathophysiology of ischemic stroke. Thromb Res 2000;98(3):73-81
7. Persidsky Y, Ramirez S, Haorah J, Kanmogne G. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 2006;1(3):223-36 (Pubitemid 44244128)
8. Wardlaw JM, Sandercock PAG, Dennis MS, Starr J. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke 2003;34(3):806-12
9. Popescu BO, Toescu EC, Popescu LM, et al. Blood-brain barrier alterations in ageing and dementia. J Neurol Sci 2009;283(1-2):99-106
10. Kooij G, van Horssen J, de Lange ECM, et al. T lymphocytes impair P-glycoprotein function during neuroinflammation. J Autoimmun 2010;34(4):416-25
11. Ramirez SH, Potula R, Fan S, et al. Methamphetamine disrupts blood-brain barrier function by induction of oxidative stress in brain endothelial cells. J Cereb Blood Flow Metab 2009;29(12):1933-45
12. Bauer B, Hartz AMS, Fricker G, Miller DS. Modulation of p-glycoprotein transport function at the blood-brain barrier. Exp Biol Med 2005;230(2):118-27
13. Greenwald ES. Organic mental changes with fluorouracil therapy. JAMA 1976;235(3):248-9
14. Han R, Yang Y, Dietrich J, et al. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol 2008;7(4):12
15. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 2010;116(14):3348-56
16. Choi SM, Lee SH, Yang YS, et al. 5-Fluorouracil-induced leukoencephalopathy in patients with breast cancer. J Korean Med Sci 2001;16:328-34
17. Fluorouracil Roche. RxMed: Pharmaceutical information, 2011. Available from: http://www.rxmed.com/ b.main/b2.pharmaceutical/b2.1. monographs/CPS- %20Monographs/ CPS-%20(General%20Monographs-% 20F)/FLUOROURACIL%20ROCHE. html [Last accessed 13 January 2012]
18. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/ GA2LEN/EDF/WAO guideline: management of urticaria. Allergy 2009;64(10):1427-43
19. Weller K, Ziege C, Staubach P, et al. H1-antihistamine up-dosing in chronic spontaneous urticaria: patients' erspective of effectiveness and side effects - a retrospective survey study. PLoS One 2011;6(9):e23931
20. Cvetkovic M, Leake B, Fromm MF, et al. OATP and p-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999;27(8):866-71 (Pubitemid 29347585)
21. Petri N, Tannergren C, Rungstad D, Lennernas H. Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm Res 2004;21(8):1398-404 (Pubitemid 39149654)
22. Zhao R, Kalvass JC, Yanni SB, et al. Fexofenadine brain exposure and the influence of blood-brain barrier p-glycoprotein after fexofenadine and terfenadine administration. Drug Metab Dispos 2009;37(3):529-35
23. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005;57(2):173-85 (Pubitemid 41043883)
24. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006;7(1):41-53 (Pubitemid 41828930)
25. Neuwelt EA, Bauer B, Fahlke C, et al. Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci 2011;12(3):169-82
26. Kalvass JC, Maurer TS. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 2002;23(8):327-38 (Pubitemid 36124162)
27. Doan KMM, Humphreys JE, Webster LO, et al. Passive permeability and p-glycoprotein-mediated efflux differentiate Central Nervous System (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 2002;303(3):1029-37 (Pubitemid 35424386)
28. Di L, Kerns EH, Carter GT. Strategies to assess blood-brain barrier penetration. Expert Opin Drug Discov 2008;3(6):677-87 (Pubitemid 351890679)
29. Hop CECA, Cole MJ, Davidson RE, et al. High throughput ADME screening: practical considerations, impact on the portfolio and enabler of in silico ADME models. Curr Drug Metab 2008;9(9):847-53
30. Keefer CE, Chang G, Kauffman GW. Extraction of tacit knowledge from large ADME data sets via pairwise analysis. Bioorg Med Chem 2011;19(12):3739-49
31. Cole S, Bagal S, El-Kattan A, et al. Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration. Xenobiotica 2012;42(1):11-27
32. Deli MA, Abraham CS, Kataoka Y, Niwa M. Permeability studies on in vitroblood-brain barrier models: physiology, pathology, and pharmacology. Cell Mol Neurobiol 2005;25(1):59-127 (Pubitemid 40558585)
33. Lippmann ES, Weidenfeller C, Svendsen CN, Shusta EV. Blood-brain barrier modeling with co-cultured neural progenitor cell-derived astrocytes and neurons. J Neurochem 2011;119(3):507-20
34. Cucullo L, Hossain M, Puvenna V, et al. The role of shear stress in blood-brain barrier endothelial physiology. BMC Neurosci 2011;12(1):40
35. Caram-Salas N, Boileau E, Farrington GK, et al. In vitro and in vivo methods for assessing FcRn-mediated reverse transcytosis cross the blood-brain barrier. Methods Mol Biol 2011;763:383-401
36. Hosoya K-I, Hori S, Ohtsuki S, Terasaki T. A new in vitro model for blood-cerebrospinal fluid barrier transport studies: an immortalized choroid plexus epithelial cell line derived from the tsA58 SV40 large T-antigen gene transgenic rat. Adv Drug Deliv Rev 2004;56(12):1875-85 (Pubitemid 39286164)
37. Klas J, Wolburg H, Terasaki T, et al. Characterization of immortalized choroid plexus epithelial cell lines for studies of transport processes across the blood-cerebrospinal fluid barrier. Cerebrospinal Fluid Res 2010;7(1):11
38. Balbuena P, Li W, Magnin-Bissel G, et al. Comparison of two blood-brain barrier in vitro systems: cytotoxicity and transfer assessments of malathion/oxon and lead acetate. Toxicol Sci 2010;114(2):260-71
39. Trickler WJ, Lantz SM, Murdock RC, et al. Silver nanoparticle induced blood-brain barrier inflammation and increased permeability in primary rat brain microvessel endothelial cells. Toxicol Sci 2010;118(1):160-70
40. Mente SR, Lombardo F. A recursive-partitioning model for blood-brain barrier permeation. J Comput Aided Mol Des 2005;19(7):465-81 (Pubitemid 43150054)
41. Adenot M, Lahana R. Blood-brain barrier permeation models: discriminating between potential CNS and non-CNS drugs including p-glycoprotein substrates. J Chem Inf Comput Sci 2004;44:239-48
42. Lobell M, Molnar L, Keseru GM. Recent advances in the prediction of blood-brain partitioning from molecular structure. J Pharm Sci 2003;92(2):360-70 (Pubitemid 36169308)
43. Doniger S, Hofmann T, Yeh J. Predicting CNS permeability of drug molecules: comparison of neural network and support vector machines. J Comput Biol 2002;9(6):849-64 (Pubitemid 36207918)
44. Platts JA, Abraham MH, Zhao YH, et al. Correlation and prediction of a large blood-brain distribution data set-an LFER study. Eur J Med Chem 2001;36:719-30 (Pubitemid 32973863)
45. Osterber T, Norinder U. Prediction of drug transport processes using simple parameters and PLS statistics: the use of ACD/logP and ACD/ChemSketch descriptors. Eur J Pharm Sci 2001;12:327-37
46. Crivori P, Cruciani G, Carrupt P-A, Testa B. Predicting blood-brain barrier permeation from three-dimensional molecular structure. J Med Chem 2000;43:2204-16 (Pubitemid 30354545)
47. Luco JM. Prediction of the brain-blood distribution of a large set of drugs from structurally derived descriptors using Partial Least-Squares (PLS) modeling. J Chem Inf Comput Sci 1999;39:396-404 (Pubitemid 129538932)
48. Norinder U, Sjoberg P, Osterberg T. Theoretical calculation and prediction of brain-blood partitioning of organic solutes using MolSurf parametrization and PLS statistics. J Pharm Sci 1998;87(8):952-9 (Pubitemid 28381252)
49. Lombardo F, Blake JF, Curatolo WJ. Computation of brain-blood partitioning of organic solutes via free energy calculations. J Med Chem 1996;39(24):4750-5 (Pubitemid 26423893)
50. Chadha H, Abraham MH, Mitchell RC. Physicochemical analysis of the factors governing distribution of solutes between blood and brain. Bioorg Med Chem Lett 1994;4(21):2511-16 (Pubitemid 24342936)
51. Abraham MH, Chadha H, Mitchell RC. Hydrogen bonding: 33. Factors that influence the distribution of solutes between blood and brain. J Pharm Sci 1994;83(9):1257-68 (Pubitemid 24282331)
52. Chen H, Winiwarter S, Friden M, et al. In silico prediction of unbound brain-to-plasma concentration ratio using machine learning algorithms. J Mol Graph Model 2011;29(8):985-95
53. Friden M, Bergstrom F, Wan H, et al. Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos 2011;39(3):353-62
54. Lanevskij K, Dapkunas J, Juska L, et al. QSAR analysis of blood-brain distribution: the influence of plasma and brain tissue binding. J Pharm Sci 2011;100(6):2147-60
55. Kelder J, Grootenhuis PDJ, Bayada DM, et al. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res 1999;16(10):1514-19 (Pubitemid 29510546)
56. Clark DE. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J Pharm Sci 1999;88(8):815-21 (Pubitemid 29398551)
57. Wager TT, Chandrasekaran RY, Hou X, et al. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem Neurosci 2010;1(6):420-34
58. Wager TT, Hou XJ, Rong H, et al. Role of P-gp in CNS drug discovery [abstract MEDI-161]. Abstracts of Papers, 241st ACS National Meeting; 27 - 31 March 2011; Anaheim, CA
59. Ghose AK, Herbertz T, Hudkins RL, et al. Knowledge-based, Central Nervous System (CNS) lead selection and lead optimization for CNS drug discovery. ACS Chem Neurosci 2012;3(1):50-68
60. Ajay, Bemis GW, Murcko MA. Designing libraries with CNS activity. J Med Chem 1999;42(24):4942-57
61. Rose K, Hall LH, Kier LB. Modeling blood-brain barrier partitioning using the electrotopological state. J Chem Inf Comput Sci 2002;42:651-6
62. Shaffer CL. Determining neuropharmacokinetic parameters in CNS drug discovery to determinecross-species pharmacologic exposure-response relationships. In: Macor JE, editor. Annu Rep Med Chem. Boston: Academic Press; 2010;45:55-70
63. De Lange ECM, Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet 2002;41(10):691-703 (Pubitemid 34948192)
64. Oyler GA, Duckrow RB, Hawkins RA. Computer simulation of the blood-brain barrier: a model including two membranes, blood flow, facilitated and non-facilitated diffusion. J Neurosci Methods 1992;44(2-3):179-96
65. Kim CS, Ross IA, Sandberg JA, Preston E. Quantitative low-dose assessment of seafood toxin, domoic acid, in the rat brain: application of physiologically-based pharmacokinetic (PBPK) modeling. Environ Toxicol Pharmacol 1998;6(1):49-58 (Pubitemid 28359519)
66. Liu X, Smith BJ, Chen C, et al. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther 2005;313(3):1254-62 (Pubitemid 40727030)
67. Hammarlund-Udenaes M, Friden M, Syvaenen S, Gupta A. On the rate and extent of drug delivery to the brain. Pharm Res 2008;25(8):1737-50
68. Fenneteau F, Turgeon J, Couture L, et al. Assessing drug distribution in tissues expressing p-glycoprotein through physiologically based pharmacokinetic modelling: model structure and parameters determination. Theor Biol Med Model 2009;6:2
69. Kuttler A, Dimke T, Kern S, et al. Understanding pharmacokinetics using realistic computational models of fluid dynamics: biosimulation of drug distribution within the CSF space for intrathecal drugs. J Pharmacokinet Pharmacodyn 2010;37(6):629-44
70. Pardridge WM. Drug transport in brain via the cerebrospinal fluid. Fluids Barriers CNS 2011;8(1):7
71. Tsinman O, Tsinman K, Sun N, Avdeef A. Physicochemical selectivity of the BBB microenvironment governing passive diffusion-matching with a porcine brain lipid extract artificial membrane permeability model. Pharm Res 2010;28(2):337-63
72. Tran TT, Mittal A, Aldinger T, et al. The elementary mass action rate constants of p-gp transport for a confluent monolayer of MDCKII-hMDR1 cells. Biophys J 2005;88(1):715-38 (Pubitemid 40070714)
73. Tran TT, Mittal A, Gales T, et al. Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modeled as a single barrier. J Pharm Sci 2004;93(8):2108-23 (Pubitemid 39045490)
74. Ito K, Uchida Y, Ohtsuki S, et al. Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. J Pharm Sci 2011;100(9):3939-50
75. Uchida Y, Ohtsuki S, Katsukura Y, et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 2011;117(2):333-45
76. Bradbury M, Begley D, Kreuter J. editors. The Blood-Brain Barrier and Drug Delivery to the CNS. New York: Marcel Dekker; 2000;93-108
77. Fagerholm U. The highly permeable blood-brain barrier: an evaluation of current opinions about brain uptake capacity. Drug Discov Today 2007;12(23&24):1076-82 (Pubitemid 350186133)
78. Kumar G, Smith QR, Hokari M, et al. Brain uptake, pharmacokinetics, and tissue distribution in the rat of neurotoxic N-butylbenzenesulfonamide. Toxicol Sci 2007;97(2):253-64 (Pubitemid 47073843)
79. Dohrmann GJ. The choroid plexus: a historical review. Brain Res 1970;18(2):197-218
80. Strazielle N, Ghersi-Egea JF. Choroid plexus in the central nervous system: biology and physiopathology. J Neuropathol Exp Neurol 2000;59(7):561-74 (Pubitemid 30457787)
81. Szentistvanyi I, Patlak CS, Ellis RA, Cserr HF. Drainage of interstitial fluid from different regions of rat brain. Am J Physiol 1984;246(6 Pt 2):F835-44 (Pubitemid 14075694)
82. Westerhout J, Danhof M, De Lange EC, et al. Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting. J Pharm Sci 2011;100(9):3577-93
83. Kandel ER, Schwartz J, Jessell T. Principles of Neural Science. New York: McGraw-Hill; 2000